iScience (Sep 2023)

Spi1 R235C point mutation confers hypersensitivity to radiation-induced acute myeloid leukemia in mice

  • Natalie Brown,
  • Rosemary Finnon,
  • Paul Finnon,
  • Roisin McCarron,
  • Lourdes Cruz-Garcia,
  • Grainne O’Brien,
  • Eleanor Herbert,
  • Cheryl L. Scudamore,
  • Edouard Morel,
  • Christophe Badie

Journal volume & issue
Vol. 26, no. 9
p. 107530

Abstract

Read online

Summary: Ionizing radiation (IR) is a risk factor for acute myeloid leukemia (rAML). Murine rAMLs feature both hemizygous chromosome 2 deletions (Del2) and point mutations (R235) within the hematopoietic regulatory gene Spi1. We generated a heterozygous CBA Spi1 R235 mouse (CBASpm/+) which develops de novo AML with 100% incidence by ∼12 months old and shows a dose-dependent reduction in latency following X-irradiation. These effects are reduced on an AML-resistant C57Bl6 genetic background. CBASpm/Gfp reporter mice show increased Gfp expression, indicating compensation for Spm-induced Spi1 haploinsufficiency. Del2 is always detected in both de novo and rAMLs, indicating that biallelic Spi1 mutation is required for AML. CBASpm/+ mice show that a single Spm modification is sufficient for initiating AML development with complete penetrance, via the “two-hit” mechanism and this is accelerated by IR exposure. Similar SPI1/PU.1 polymorphisms in humans could potentially lead to enhanced susceptibility to IR following medical or environmental exposure.

Keywords